BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 19118045)

  • 21. N-(2,6-dimethoxypyridine-3-yl)-9-methylcarbazole-3-sulfonamide as a novel tubulin ligand against human cancer.
    Wang YM; Hu LX; Liu ZM; You XF; Zhang SH; Qu JR; Li ZR; Li Y; Kong WJ; He HW; Shao RG; Zhang LR; Peng ZG; Boykin DW; Jiang JD
    Clin Cancer Res; 2008 Oct; 14(19):6218-27. PubMed ID: 18829501
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expansile nanoparticles: synthesis, characterization, and in vivo efficacy of an acid-responsive polymeric drug delivery system.
    Griset AP; Walpole J; Liu R; Gaffey A; Colson YL; Grinstaff MW
    J Am Chem Soc; 2009 Feb; 131(7):2469-71. PubMed ID: 19182897
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preclinical development of the nicotinamide phosphoribosyl transferase inhibitor prodrug GMX1777.
    Beauparlant P; Bédard D; Bernier C; Chan H; Gilbert K; Goulet D; Gratton MO; Lavoie M; Roulston A; Turcotte E; Watson M
    Anticancer Drugs; 2009 Jun; 20(5):346-54. PubMed ID: 19369827
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of human non-small cell lung cancers with a targeted cytotoxic somatostatin analog, AN-162.
    Treszl A; Schally AV; Seitz S; Szalontay L; Rick FG; Szepeshazi K; Halmos G
    Peptides; 2009 Sep; 30(9):1643-50. PubMed ID: 19524629
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro optimization of non-small cell lung cancer activity with troxacitabine, L-1,3-dioxolane-cytidine, prodrugs.
    Radi M; Adema AD; Daft JR; Cho JH; Hoebe EK; Alexander LE; Peters GJ; Chu CK
    J Med Chem; 2007 May; 50(9):2249-53. PubMed ID: 17419604
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preclinical analysis of tasidotin HCl in Ewing's sarcoma, rhabdomyosarcoma, synovial sarcoma, and osteosarcoma.
    Garg V; Zhang W; Gidwani P; Kim M; Kolb EA
    Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5446-54. PubMed ID: 17875774
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modulating the therapeutic activity of nanoparticle delivered paclitaxel by manipulating the hydrophobicity of prodrug conjugates.
    Ansell SM; Johnstone SA; Tardi PG; Lo L; Xie S; Shu Y; Harasym TO; Harasym NL; Williams L; Bermudes D; Liboiron BD; Saad W; Prud'homme RK; Mayer LD
    J Med Chem; 2008 Jun; 51(11):3288-96. PubMed ID: 18465845
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel nontoxic heat shock protein 90 inhibitors having selective antiproliferative effect.
    Orosz A; Szabo A; Szeman G; Janaky T; Somlai C; Penke B; Bodor A; Perczel A
    Int J Biochem Cell Biol; 2006; 38(8):1352-62. PubMed ID: 16540363
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel.
    Desai N; Trieu V; Yao Z; Louie L; Ci S; Yang A; Tao C; De T; Beals B; Dykes D; Noker P; Yao R; Labao E; Hawkins M; Soon-Shiong P
    Clin Cancer Res; 2006 Feb; 12(4):1317-24. PubMed ID: 16489089
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel DNA-directed alkylating agents: design, synthesis and potent antitumor effect of phenyl N-mustard-9-anilinoacridine conjugates via a carbamate or carbonate linker.
    Kapuriya N; Kapuriya K; Dong H; Zhang X; Chou TC; Chen YT; Lee TC; Lee WC; Tsai TH; Naliapara Y; Su TL
    Bioorg Med Chem; 2009 Feb; 17(3):1264-75. PubMed ID: 19124250
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Abilities of 3,4-diarylfuran-2-one analogs of combretastatin A-4 to inhibit both proliferation of tumor cell lines and growth of relevant tumors in nude mice.
    Sun L; Vasilevich NI; Fuselier JA; Coy DH
    Anticancer Res; 2004; 24(1):179-86. PubMed ID: 15015595
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The use of biotinylated-EGF-modified gelatin nanoparticle carrier to enhance cisplatin accumulation in cancerous lungs via inhalation.
    Tseng CL; Su WY; Yen KC; Yang KC; Lin FH
    Biomaterials; 2009 Jul; 30(20):3476-85. PubMed ID: 19345990
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity.
    Doronina SO; Mendelsohn BA; Bovee TD; Cerveny CG; Alley SC; Meyer DL; Oflazoglu E; Toki BE; Sanderson RJ; Zabinski RF; Wahl AF; Senter PD
    Bioconjug Chem; 2006; 17(1):114-24. PubMed ID: 16417259
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative.
    Hollingshead M; Alley M; Burger AM; Borgel S; Pacula-Cox C; Fiebig HH; Sausville EA
    Cancer Chemother Pharmacol; 2005 Aug; 56(2):115-25. PubMed ID: 15791458
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Thermoresponsive and biodegradable linear-dendritic nanoparticles for targeted and sustained release of a pro-apoptotic drug.
    Stover TC; Kim YS; Lowe TL; Kester M
    Biomaterials; 2008 Jan; 29(3):359-69. PubMed ID: 17964645
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intravesical chemotherapy of high-grade bladder cancer with HTI-286, a synthetic analogue of the marine sponge product hemiasterlin.
    Hadaschik BA; Adomat H; Fazli L; Fradet Y; Andersen RJ; Gleave ME; So AI
    Clin Cancer Res; 2008 Mar; 14(5):1510-8. PubMed ID: 18316576
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tubulin-targeted drug action: functional significance of class ii and class IVb beta-tubulin in vinca alkaloid sensitivity.
    Gan PP; Kavallaris M
    Cancer Res; 2008 Dec; 68(23):9817-24. PubMed ID: 19047161
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Screening and identification of a peptide specifically targeted to NCI-H1299 from a phage display peptide library.
    Zang L; Shi L; Guo J; Pan Q; Wu W; Pan X; Wang J
    Cancer Lett; 2009 Aug; 281(1):64-70. PubMed ID: 19327883
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selective tumor targeting by the hypoxia-activated prodrug AQ4N blocks tumor growth and metastasis in preclinical models of pancreatic cancer.
    Lalani AS; Alters SE; Wong A; Albertella MR; Cleland JL; Henner WD
    Clin Cancer Res; 2007 Apr; 13(7):2216-25. PubMed ID: 17404106
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthesis of linear, beta-cyclodextrin-based polymers and their camptothecin conjugates.
    Cheng J; Khin KT; Jensen GS; Liu A; Davis ME
    Bioconjug Chem; 2003; 14(5):1007-17. PubMed ID: 13129405
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.